在所有非小细胞肺癌(NSCLC)中,MET 14 号外显子跳跃突变(exon 14 skipping,exon14Δ)率为 3% ~ 4%,而在恶性程度高、预后极差的肺肉瘤样癌(pulmonary sarcomatoid carcinoma,PSC)中,其突变率更是高达 4.9% ~ 31.8%[1]。今年 ASCO 年会...
引自:Fujino T, Suda K, Mitsudomi T. Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges. Lung Cancer (Auckl). 2021 May 20;12:35-50. doi: 10.2147/LCTT.S269307. PMID: 34295201; PMCID: PMC8290191. 3.2各区域突变导致MET exon14 skippi...
[4] Cortot AB, Kherrouche Z, Descarpentries C et al. Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. J Natl Cancer Inst. 2017 May 1;109(5). [5] Fujino T, Suda K, Mitsudomi T. Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatm...
[4] Cortot AB, Kherrouche Z, Descarpentries C et al. Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. J Natl Cancer Inst. 2017 May 1;109(5). [5] Fujino T, Suda K, Mitsudomi T. Lung Cancer with MET exon 14 Skipp...
2.MET14跳突NSCLC的检测方法 3.MET14跳突NSCLC的流行病学特征 4.METex14跳突非小细胞肺癌的患者的临床特征和患者特征 5.临床疗效结果 讨论: 结论: 参考文献: 今天分享下2023年6月12日发表在Clinical Lung Cancer针对MET14跳突的《MET exon 14 skipping in NSCLC: A systematic literature review of epidemiology...
7.Yongfeng Yu, Jianya Zhou, Xingya Li, et al. Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial.EClinicalMedicine.v.59; 2023 May.8.国家药品监督管理局药品审评中心（CDE）官网.
[3]Socinski MA, Pennell NA, Davies KD. MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. JCO Precis Oncol. 2021;5:PO.20.00516. [4]韩森,马旭,方健.非小细胞肺癌MET基因突变的机制及靶向药物研究进展[J].中国肺...
[1]. 非小细胞肺癌MET临床检测中国专家共识. [2]. Subramanian J, Tawfik O. Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective. Expert Rev Anticancer Ther. 2021 Aug;21(8):877-886. ...
[8] Socinski MA, Pennell NA, Davies KD. MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. JCO Precis Oncol. 2021 Apr 13;5:PO.20.00516. [9] Liu SY, Gou LY, Li AN et al. The unique characteristics of...
1]《非小细胞肺癌MET临床检测中国专家共识》。中华病理学杂志,2022年11月,第51卷,第11期。 2] NCCN指南,非小细胞肺癌,2022,V3。 3] MET receptor in oncology: From biomarker to therapeutic target. Adv Cancer Res. 2020;147:259-301. 4] Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feat...